

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(10) International Publication Number
WO 2021/206965 A1

(43) International Publication Date
14 October 2021 (14.10.2021)

(51) International Patent Classification:

A61K 39/395 (2006.01) *A61K 47/26* (2006.01)
A61K 47/10 (2017.01) *C07K 16/28* (2006.01)
A61K 47/12 (2006.01) *C07K 16/30* (2006.01)

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(21) International Application Number:

PCT/US2021/024937

(22) International Filing Date:

30 March 2021 (30.03.2021)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/005,755 06 April 2020 (06.04.2020) US

(71) Applicants: **THE BOARD OF TRUSTEES OF THE LE-
LAND STANFORD JUNIOR UNIVERSITY** [US/US];
Office of the General Counsel, Building 170, 3rd
Floor, Main Quad, P.O. Box 20386, Stanford, California
94305-2038 (US). **FORTY SEVEN, INC.** [US/US]; 333
Lakeside Drive, Foster City, California 94404 (US).

(72) Inventors: **MAJETI, Ravindra**; 265 Campus Drive,
Lokey Stem Cell Research Building, G3021B, Stanford,
California 94305 (US). **WEISSMAN, Irving L.**; 747 Santa
Ynez Street, Stanford, California 94305 (US). **NGUYEN,
Phuong**; 415 Broadway Street, 2nd Floor, MC8854, Red-
wood City, California 94063 (US).

(74) Agent: **SHERWOOD, Pamela J.**; 201 Redwood Shores
Parkway, Suite 200, Redwood City, California 94065 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN,
KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: ANTIBODY FORMULATION

(57) Abstract: Formulations of anti-CD47 antibodies having a pharmacologically acceptable concentration and stable shelf life are provided.

